Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Grapiprant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 known ✓ | P35408 | 7/20 | 1.00 |
| ▸ | CA12 | O43570 | 4/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Grapiprant SCHEMBL29496330 | 1.00 | PTGER4 (1.00) | PTGER4CA12CA1CA2CA9 | |
| SCHEMBL23876504 | 0.96 | PTGER4 (0.92) | PTGER4CA12CA1CA2CA9 | |
| SCHEMBL30225045 | 0.96 | PTGER4 (0.92) | PTGER4CA12CA1CA2CA9 | |
| SCHEMBL23089764 | 0.96 | PTGER4 (0.92) | PTGER4CA12CA1CA2CA9 | |
| SCHEMBL1626042 | 0.93 | PTGER4 (0.87) | PTGER4CA12CA1CA2CA9 | |
| SCHEMBL23876638 | 0.92 | PTGER4 (0.84) | PTGER4CA12CA1CA2CA9 | |
| SCHEMBL1624996 | 0.91 | PTGER4 (0.84) | PTGER4CA12CA1CA2CA9 | |
| SCHEMBL23876535 | 0.91 | PTGER4 (0.84) | PTGER4CA12CA1CA2CA9 | |
| SCHEMBL23109130 | 0.91 | PTGER4 (0.83) | PTGER4CA12CA1CA2CA9 | |
| SCHEMBL1624619 | 0.90 | PTGER4 (0.82) | PTGER4CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1025 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486292-B2 | Prodrug platform useful to deliver amines, amides and phenols | Changchun Changcheng Pharmaceutical Technology Co., LTD (CN) | 2025-12-02 | — | — | US | claimed |
| US-12478633-B2 | Compositions of grapiprant and methods for using the same | Aratana Therapeutics, Inc. (US) | 2025-11-25 | — | — | US | claimed |
| CN-120195315-A | Ma Luopi concentration and content detection method based on canine plasma | 北京远大星火医药科技有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-116478155-B | Preparation method of grapiprant and intermediate thereof | 洛阳惠中兽药有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-116046930-B | High performance liquid chromatography analysis method for detecting grapiprant content | 丽珠集团新北江制药股份有限公司 | 2025-04-29 | — | — | CN | claimed |
| US-20250025481-A1 | COMPOSITIONS OF GRAPIPRANT AND METHODS FOR USING THE SAME | Aratana Therapeutics, Inc. | 2025-01-23 | — | — | US | claimed |
| US-20250009764-A1 | COMPOSITIONS OF GRAPIPRANT AND METHODS FOR USING THE SAME | ARATANA THERAPEUTICS INC. | 2025-01-09 | — | — | US | claimed |
| CN-119060046-A | Pharmaceutical preparation containing grapiprant hydrochloride and preparation method thereof | 洛阳惠中兽药有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-118987015-A | Application of antisense oligonucleotide in preparation of medicine for treating breast cancer | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| US-20240342196-A1 | TARGETING SELECT LIPID SIGNALING TO COUNTER TYPE 1 DIABETES (T1D) | UAB RES FOUND (US) | 2024-10-17 | — | — | US | claimed |
| US-7148234-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2006-12-12 | — | — | US | claimed |
| US-7141580-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2006-11-28 | — | — | US | claimed |
| WO-2006095268-A1 | CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE | PFIZER JAPAN INC. (JP) | 2006-09-14 | — | — | WO | claimed |
| EP-1326864-B1 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMA (JP) | 2006-03-15 | — | — | EP | claimed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | claimed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | claimed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | claimed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | claimed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009764-A1 | COMPOSITIONS OF GRAPIPRANT AND METHODS FOR USING THE SAME | OPRL1, PIGS, GMPS | PTGER4 111/4885CA12 3315/4885CA1 3895/4885 |
| US-20250025481-A1 | COMPOSITIONS OF GRAPIPRANT AND METHODS FOR USING THE SAME | OPRL1, PIGS, GMPS | PTGER4 111/4885CA12 3315/4885CA1 3895/4885 |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | PTGER4 51/4885CA12 2074/4885CA1 2229/4885 |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | PTGER4 55/4885CA12 2132/4885CA1 2298/4885 |
| US-12486292-B2 | Prodrug platform useful to deliver amines, amides and phenols | GOT1, PAM, GLS2 | PTGER4 3106/4885CA12 2891/4885CA1 3108/4885 |
| US-12478633-B2 | Compositions of grapiprant and methods for using the same | OPRL1, PIGS, GMPS | PTGER4 111/4885CA12 3315/4885CA1 3895/4885 |
| US-20240342196-A1 | TARGETING SELECT LIPID SIGNALING TO COUNTER TYPE 1 DIABETES (T1D) | DGKB, PLIN1, SPTLC1 | PTGER4 3285/4885CA12 4864/4885CA1 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.